Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

283 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I. Pujade-Lauraine E, et al. Among authors: wimberger p. J Clin Oncol. 2014 May 1;32(13):1302-8. doi: 10.1200/JCO.2013.51.4489. Epub 2014 Mar 17. J Clin Oncol. 2014. PMID: 24637997 Clinical Trial.
Impact of age on outcome in patients with advanced ovarian cancer treated within a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
Wimberger P, Lehmann N, Kimmig R, Burges A, Meier W, Hoppenau B, du Bois A; AGO-OVAR. Wimberger P, et al. Gynecol Oncol. 2006 Feb;100(2):300-7. doi: 10.1016/j.ygyno.2005.08.029. Epub 2005 Sep 29. Gynecol Oncol. 2006. PMID: 16199079 Clinical Trial.
Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
Wimberger P, Lehmann N, Kimmig R, Burges A, Meier W, Du Bois A; Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. Wimberger P, et al. Gynecol Oncol. 2007 Jul;106(1):69-74. doi: 10.1016/j.ygyno.2007.02.026. Epub 2007 Mar 29. Gynecol Oncol. 2007. PMID: 17397910 Clinical Trial.
Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group).
Wimberger P, Wehling M, Lehmann N, Kimmig R, Schmalfeldt B, Burges A, Harter P, Pfisterer J, du Bois A. Wimberger P, et al. Ann Surg Oncol. 2010 Jun;17(6):1642-8. doi: 10.1245/s10434-010-0964-9. Epub 2010 Feb 18. Ann Surg Oncol. 2010. PMID: 20165986
Prognostic role of platinum sensitivity in patients with brain metastases from ovarian cancer: results of a German multicenter study.
Sehouli J, Pietzner K, Harter P, Münstedt K, Mahner S, Hasenburg A, Camara O, Wimberger P, Boehmer D, Buehling KJ, Richter R, El Khalfaoui K, Oskay-Ozcelik G. Sehouli J, et al. Among authors: wimberger p. Ann Oncol. 2010 Nov;21(11):2201-2205. doi: 10.1093/annonc/mdq229. Epub 2010 May 3. Ann Oncol. 2010. PMID: 20439341 Free article.
Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer.
du Bois A, Herrstedt J, Hardy-Bessard AC, Müller HH, Harter P, Kristensen G, Joly F, Huober J, Avall-Lundqvist E, Weber B, Kurzeder C, Jelic S, Pujade-Lauraine E, Burges A, Pfisterer J, Gropp M, Staehle A, Wimberger P, Jackisch C, Sehouli J. du Bois A, et al. Among authors: wimberger p. J Clin Oncol. 2010 Sep 20;28(27):4162-9. doi: 10.1200/JCO.2009.27.4696. Epub 2010 Aug 23. J Clin Oncol. 2010. PMID: 20733132 Clinical Trial.
283 results